When potassium levels remain low, potassium deficiency can quietly worsen insulin sensitivity, contributing to insulin resistance and impaired glucose tolerance even in people without obvious diabetes. Clinically, hypokalemia has been associated with higher fasting glucose and insulin levels, and with a greater risk of developing new‑onset diabetes in patients on potassium‑wasting diuretics compared with those whose potassium is better maintained. The encouraging piece is that correcting low potassium, alongside other lifestyle and medical strategies, can improve insulin action and glycemic control in some individuals, suggesting that unrecognized potassium deficiency may be a modifiable piece of the insulin‑resistance puzzle. This medication is commonly used for Hypertension.
Plavinik FL, Rodrigues CI, Zanella MT, Ribeiro AB. Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. Hypertension. 1992 Feb;19(2 Suppl):II26-9. Phillip Gorden; Glucose Intolerance with Hypokalemia: Failure of Short-term Potassium Depletion in Normal Subjects to Reproduce the Glucose and Insulin Abnormalities of Clinical Hypokalemia. Diabetes 1 July 1973; 22 (7): 544–551. Heianza Y, Hara S, Arase Y, Saito K, Totsuka K, Tsuji H, Kodama S, Hsieh SD, Yamada N, Kosaka K, Sone H. Low serum potassium levels and risk of type 2 diabetes: the Toranomon Hospital Health Management Center Study 1 (TOPICS 1). Diabetologia. 2011 Apr;54(4):762-6. Chatterjee R, Yeh HC, Shafi T, Selvin E, Anderson C, Pankow JS, Miller E, Brancati F. Serum and dietary potassium and risk of incident type 2 diabetes mellitus: The Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2010 Oct 25;170(19):1745-51.
Some side effects may be linked to nutrient depletion caused by this medication.
An increased excretion of potassium can occur in people taking calcium channel blocker drugs like felodipine. Supplementation may need to be considered if blood levels of potassium are low.
Studies suggest that Felodipine, a type of calcium channel blocker (CCB), may increase the excretion of calcium in the urine. While the long-term effects on bone health are unclear, some healthcare professionals suggest calcium supplementation for patients taking felodipine, especially those at higher risk of osteoporosis.
Research suggests that Felodipine, a type of calcium channel blocker (CCB), may increase the excretion of magnesium in the urine. This can potentially lead to magnesium deficiency. Studies have shown an increase in fractional excretion of magnesium following felodipine treatment, and the drug may also alter how magnesium moves across red blood cell membranes. Therefore supplementation with magnesium should be considered when on this therapy.